Comments on and illustrations of the WFUMB CEUS liver guidelines: Rare malignant mesenchymal liver lesions

Ehsan Safai Zadeh¹, Thomas Friedrich², Christian Görg³, Katharina Paulina Huber⁴, Kathleen Möller⁵, Analisa Berzigotti⁶, Thomas Thomsen⁷, Christian Jenssen⁸, Ernst-Michael Jung⁹, Adrian Lim¹⁰, Masayuki Kitano¹¹, Ryo Shimizu¹², Yi Dong¹³, Xin Wu Cui¹⁴, David Srivastava²,¹⁵, Christoph F Dietrich²

¹Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, ²Department Allgemeine Innere Medizin, Kliniken Hirslanden, Beau Site, Salem und Permanence, Bern, Switzerland, ³Interdisciplinary Center of Ultrasound Diagnostics, University Hospital Giessen and Marburg, Philipps University Marburg, Baldingerstraße, Marburg, Germany, ⁴Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, Germany, ⁵Medical Department I/Gastroenterology; SANA Hospital Lichtenberg, Berlin, Germany, ⁶Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland, ⁷Department of Internal Medicine, Westküstenkliniken, Brunsbüttel, Germany, ⁸Medical Department, Krankenhaus Maerkisch-Oderland, Strausberg, Brandenburg Institute of Clinical Medicine at Medical University Brandenburg, Brandenburg, Germany, ⁹Department of Radiology, University Medical Center Regensburg, Germany, ¹⁰Imperial College London and Healthcare NHS Trust, London, UK, ¹¹Second Department of Internal Medicine, Wakayama Medical University, Japan, ¹²Second Department of Internal Medicine, Wakayama Medical University, Japan, ¹³Department of Ultrasound, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ¹⁴Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ¹⁵Inselspital, Bern, Switzerland

Abstract

The diagnosis or rare mesenchymal malignant lesions of the liver may be a challenge owing to the rarity of the disease and is usually made by histological confirmation. An ultrasound examination with, if required, color Doppler sonography and contrast-enhanced ultrasound, taking into account the clinical background of the patient, may help to focus the differential diagnosis. In this review, we describe the pathological and ultrasound features of several rare mesenchymal malignant liver lesions which include undifferentiated sarcoma of the liver, leiomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, and epithelioid hemangioendothelioma.

Keywords: ultrasound; CEUS; diagnosis; liver; mesenchymal malignant lesion

Introduction

The World Federation for Ultrasound in Medicine and Biology (WFUMB) has published guidelines on...
cellular carcinoma [12,13], very small HCC (<10 mm) [14], mixed HCC and cholangiocellular carcinoma [15], nodular regenerative hyperplasia [16], sarcoma [17], inflammatory pseudotumour [18], sarcoidosis [19-22], tuberculosis [23,24], hydatid cysts [25-28], alveolar echinococcosis [26], schistosomiasis [29,30], ascariasis [31,32], fascioliasis [33], clonorchis and opisthorchis [34], toxocariasis [35], bacillary angiomatosis [36], and amyloidosis with spontaneous hemorrhage [37], as well as rare FLLs in pediatric patients [38,39] and further published comments and illustrations of the WFUMB CEUS guidelines [40-46].

Rare non-hematological malignant lesions of the liver include those of mesenchymal origin, such as undifferentiated sarcoma of the liver, leiomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, epithelioid hemangioendothelioma and neuroendocrine tumors, hepatoblastoma and cystadenocarcinomas of the liver. In this review, we describe the pathologic and US features of rare malignant mesenchymal liver lesions. However, it must be pointed out that the majority of descriptions of tumor features on imaging modalities are based on single causalities or small case series.

**Sarcomas of the liver**

Primary sarcomas of the liver are rare. They represent approximately 2% of all hepatic malignancies [47,48]. Hepatic sarcomas must be differentiated from other tumor entities, especially spindle cell dedifferentiated/pleomorphic cell carcinomas, and occasionally also from amelanotic malignant melanomas or aggressive non-Hodgkin’s lymphomas, as well as from inflammatory pseudotumors and monomorphic angiomylipomas [48]. Particularly in gastrointestinal stromal tumors or even in leiomyosarcomas, liver metastases may be the first clinical manifestation of an unknown primary tumor [48]. Due to their rarity and varied morphologic appearance, sarcomas in the liver present a particular morphological challenge, especially in biopsy material [48].

Liver metastases occur comparatively rarely in sarcomas, in contrast to lung metastases. They occur mainly in intra-abdominal or visceral and in retroperitoneal sarcomas, whereas, in sarcomas of the head and neck, trunk, and extremities, pulmonary metastases are the most common [48]. In a collective of 4270 patients with soft tissue sarcomas (age range 15–91 years) treated at Memorial Sloan-Kettering Cancer Center in New York, NY, USA, over the period 1982–2000, the incidence of liver metastases was nearly 8% [48,49]. Furthermore, in the data from major reviews of surgical resection of liver metastases from 1995 to 2000, the proportion of sarcoma metastases was approximately 1% [48,50].

**Undifferentiated (embryonal) sarcoma of the liver**

Undifferentiated (embryonal) sarcomas of the liver are extremely rare primary liver tumors originating from undifferentiated malignant mesenchymal cells [51]. The disease represents only 0.1% of surgically excised primary liver lesions [51,52]. They mainly occur in children between 6 and 10 years of age and are the fourth most common liver tumors of childhood, with a frequency of 6–13% [48,53,54]. The disease is rarely reported in adults and accounts for less than 1% of all primary liver neoplasms [51,55]. The etiology of the disease is unclear. Mesenchymal hamartoma and undifferentiated sarcoma are described as entities of the same disease spectrum due to their same cytogenetic anomaly [51]. The clinical symptoms of the patients are non-specific. The patients may report symptoms such as abdominal pain, fever, and hepatomegaly [51]. Furthermore, the laboratory tests and the features in imaging methods are non-specific, and therefore the preoperative misdiagnosis rate is high. The final diagnosis of the disease is usually made based on histopathology and immunohistochemistry. Therefore, at the time of diagnosis, most patients are already in an advanced stage. Furthermore, the postoperative recurrence rate of the disease is high. The overall prognosis is described as poor, and the survival rate is low, at 37% [51]. The treatment of choice is radical resection of the tumor with adjuvant chemotherapy [51].

**Cross-sectional imaging**

On CT, the lesions are detected as cystic, solid, mixed, hypodense masses [51]. The solid components may show mild or marked enhancement in the arterial phase of the contrast-enhanced CT [51]. The enhancement may be increased in the venous phase but still less than that of the surrounding liver parenchyma [51]. On magnetic resonance imaging (MRI), lesions may show mixed intensity of high and low signals [56]. The cysts present as low signal intensity on T1-weighted images and high signal intensity on T2-weighted images [56]. Positron emission tomography (PET) can detect the uptake of 2-(fluorine-18)-fluoro-2-deoxy-D-glucose in the solid components of the tumor [56].

**B-mode US and CEUS**

On B-mode US, the lesions are visualized as solid with cystic components [51]. Furthermore, infiltration of the hepatic veins can be observed. On CEUS, the lesions may show inhomogeneous enhancement with a washout phenomenon in the parenchymal phase (fig 1).

**Leiomyosarcoma**

Primary hepatic leiomyosarcoma (PHL) is a rare malignant tumor. Between 6% and 16% of primary hep-
Patic sarcomas are PHLs [57]. PHLs originate from the smooth muscle cells of vascular structures or bile ducts [57-60]. The etiology of the disease is yet unknown. Due to the non-specific symptoms and its rarity, diagnosis of this disease is often difficult [60,61]. The only curative therapy of PHL is radical surgical resection. However, the majority of unoperated patients technically have a non-resectable condition or extra-hepatic distant metastases [57,62]. The role of chemotherapy for neoadjuvant, adjuvant, or palliative purposes in PHL, as well as in leiomyosarcomas in general, remains unclear. Furthermore, the role of liver transplantation is controversial [57]. Transarterial chemoembolization (TACE) may present a further therapy option for PHL [63]. Although the overall prognosis is poor, surgical resection of the leiomyosarcoma is associated with a 5-year survival probability of 65.2% [64]. Therefore, several authors have recommended aggressive surgical interventions, including repeated resections and debulking, even when metastases are present [65].

Cross-sectional imaging

The imaging features of PHL are non-specific and may mimic more common primary liver tumors such as HCC and cholangiocarcinoma [57]. CT may show a well-defined, heterogeneous, and hypodense lesion. Contrast-enhanced CT may reveal peripheral enhancement, or a cystic lesion with an enhanced, thickened wall [57,66]. In some case reports, multiple tortuous vessels have also been reported during the arterial phase [67].

On MRI, the lesions reveal a heterogeneous pattern and are hypointense on T1-weighted images and hyperintense on T2-weighted images without a capsule. Contrast-enhanced MRI reveals a large multilobulated, well-marginated, solid, cystic lesion from the liver with a large exophytic component in the subhepatic region that is hypointense on T1-weighted imaging and mildly hyperintense on T2-weighted imaging [68]. On contrast-enhanced MRI, the lesions show no enhancement during the arterial and portal venous phases, with evident enhancement during the 5-minute delayed phase [69]. Angiography indicates a relatively avascular mass or a vascular tumor without any shunting [65].

PET/CT demonstrates increased fluorodeoxyglucose metabolism in these lesions [69]. Finally, PHL presents as a hypovascular tumor and exhibits no tumor stains in digital subtraction angiography. However, further studies are required to confirm these findings [69].

B-mode US and CEUS

In a case report described by Lv et al, US images revealed well-defined, inhomogeneous, hypoechoic lesions with absent flow signal on CDS [69]. On CEUS, they may show nearly absent enhancement with a small rim.
Comments on the WFUMB CEUS liver guidelines: Rare malignant mesenchymal liver lesions

Angiosarcoma

Primary hepatic angiosarcoma (PHA) is an extremely rare hepatic malignant neoplasm originating from endothelial and fibroblastic tissue; it is primarily composed of abundant vasculature [71,72]. The liver is the fifth most common location of angiosarcomas, which are the most common mesenchymal malignancy of the liver. PHAs account for approximately 0.1%–2% of all malignant liver tumors, with a male:female ratio of 3–4:1. In 25% of cases, there is an association with chemical carcinogens, particularly vinylchloride, Thorotrust, and arsenic [72,73].

Although surgical resection remains the only curative treatment, it is difficult to perform because 80% of the patients are at an advanced stage at diagnosis. Chemotherapy and TACE are considered palliative treatment options. Liver transplantation is not recommended owing to the high rate of recurrence and rapid progression of the tumor, with a post-transplantation survival period of less than 7 months [74]. Furthermore, PHA is associated with a poor prognosis. The prognosis of patients with hepatic angiosarcoma depends mainly on tumor histology and the possibility of performing a total tumor resection.

Cross-sectional imaging

Most of the lesions are hypoattenuating on CT, but there is a 17–27% incidence [17] of spontaneous intraperitoneal or intratumoral hemorrhage. Therefore, some tumors may appear hyperdense [75]. Furthermore, the dominant tumors usually exhibit inhomogeneous enhancement, suggesting central necrosis or hemorrhage, and delayed progressive enhancement [71]. Curvilinear calcification is found in some lesions. Angiosarcomas show areas of high signal intensity on T1-weighted images, and a markedly inhomogeneous architecture can be observed on T2-weighted images [66]. Inhomogeneous signal intensities and central septal-like progressive enhancement on MRI should raise the possibility of a hepatic angiosarcoma [76].

B-mode US and CEUS

On B-mode US, PHA may present as an inhomogeneous, hypoechoic, and blurred lesion with patchy macrocalcification [77-79]. On CEUS, the lesions may exhibit peripheral irregular arterial enhancement with some central unenhanced areas (fig 2). Peripheral enhancement declines gradually in the portal phase and is washed out entirely in the late phase [77-79].

Liposarcoma

Primary liposarcomas of the liver are rare. They were first reported in 1973 by Wolloch et al, and since then only 14 case reports of this disease have been described, to the best of our knowledge [80]. Primary liposarcoma is a malignant tumor of adipocyte differentiation. However, because the liver generally does not contain adipocytes, hepatic or circulating mesenchymal stem cells and hepatic progenitor cells have been discussed as possible origins of the adipocytic cells in primary hepatic liposarcoma [80]. The clinical features of hepatic liposarcoma are jaundice, fever, vomiting, nausea, abdominal fullness, abdominal pain, and unclear weight loss [81]. Surgical resection with negative surgical margins is considered the method of choice in the treatment of primary hepatic liposarcoma. The role of adjuvant therapy has been described as unclear [81]. The use of radiotherapy is possible; however, as the liver can tolerate only a limited dose of radiation, it may be harmful and dangerous [81]. The 5-year survival rate of patients after curative surgical resection or radiotherapy is approximately 50% [81]. In general, the prognosis without treatment is described as poor.

Fig 2. A 64-year-old female patient with a complex hepatic mass and upper abdominal pain. Visualization of the lesion on computed tomography (courtesy of Prof. Dr. Mahnken, Department of Radiology, University Hospital Marburg) (A) and B-mode ultrasound (B). On contrast-enhanced ultrasound, the lesion shows arterial “garland-like” enhancement after 20 s (C), with increasing enhancement of the mass after 30 s (D). An ultrasound-guided biopsy was performed (E), and the diagnosis of primary angiosarcoma of the liver was confirmed histologically.
Cross-sectional imaging
On CT, the lesions are visualized as well-demarcated, almost fatty, lobulated, round masses, with some randomly distributed vascular structures [81]. On T1- and T2-weighted axial MRI, the lesions can be visualized as a hyperintense mass. The lesions may show signal loss on the fat-saturated T1-weighted axial image and enhancement of the small nodular lesions on the dynamic post-contrast fat-saturated T1-weighted axial images [81].

B-mode US and CEUS
Data regarding imaging of primary liposarcomas are very limited and refer to a few case reports; secondary liver metastases of liposarcomas are more frequent. On US, the lesions are seen as well-defined echogenic lesions [81]. On CEUS, the lesions may show inhomogeneous enhancement with a washout phenomenon in the parenchymal phase (fig 3).

Fibrosarcoma
Hepatic fibrosarcoma (HF) is extremely rare, with high malignancy and a poor prognosis. Fibrosarcoma is a soft tissue sarcoma originating from fibroblasts with variable collagen production and, in typical cases, a “herringbone architecture” [82]. The perivascular connective tissue, cellular elements of vessels, perilymphatic tissue, connective tissue of the portal vein, regenerative nodules in the case of cirrhosis, and the wall of a cystic lesion or abscess are considered to be the sites of HF origin [83]. Surgery is considered the most effective treatment, and postoperative chemotherapy is recommended for patients with infiltration or metastasis [84]. Cross-sectional imaging
On contrast-enhanced CT scans, HF may be visualized as homogeneous low-density lesions that may show an inhomogeneous enhancement or a hyperenhancement and arteriovenous shunts [84].

B-mode US and CEUS
US usually indicates a large mass in the liver, with complex echogenicity owing to hemorrhage, necrosis, or cystic degeneration [86]. On CDS, vessels may be detected [84]. On CEUS, the lesions may present with inhomogeneous enhancement during the arterial phase and hypoenhancement during the portal and delayed phase [84].

Epithelioid hemangioendothelioma
With an incidence of less than 0.1 per 100,000 population, hepatic epithelioid hemangioendothelioma (HEHE) is a very rare intermediate-malignant vascular tumor of epithelioid origin that primarily involves the liver [87,88]. It was first reported by Ishak et al in a series of 32 patients as a primary liver tumor, usually presenting as multiple hepatic lesions mimicking metastases and with low to moderate malignancy [87]. This tumor primarily affects middle-aged women, with a notably variable clinical course ranging from incidental discovery in completely asymptomatic individuals to a rapid and fatal progression involving bleeding and liver insufficiency [89]. Histologically, HEHE consists of dendritic and epithelioid cells, which mainly proliferate in the periphery of the tumor, often invading and obliterating sinusoids and branches of the portal and hepatic veins. By contrast, the central areas usually consist of fibrous and hypovascularized stroma [90]. Depending on the disease stage, HEHE may appear on imaging as a single nodular lesion or, much more commonly, as multiple nodular lesions, which may be confluent with a diffuse aspect, usually lo-
calized in the subcapsular regions [91]. Retraction of the liver capsule is a typical feature of HEHE, observed in approximately 25% of cases, and calcification has been reported in approximately 23% of patients [92,93].

Cross-sectional imaging

On CT, HEHE lesions are hypoattenuating, with a halo or target pattern of enhancement in large lesions [91]. On MRI, the lesions appear hypointense on T1-weighted unenhanced imaging, and, on T2-weighted images, they display heterogeneously increased signal intensity [91]. With gadolinium-enhanced MRI, the lesions may demonstrate target-type enhancement with a peripheral halo or thin peripheral hypointense rim. The “lollipop sign” seems to be specific to HEHE and indicates the aspect of a hepatic or portal vein terminating at the periphery of the liver lesions [94]. In most cases, the specificity of radiological findings is still insufficient to enable the differentiation of this exceptionally rare tumor from other FLLs, particularly from metastatic carcinoma, HCC, angiosarcoma, and atypical hepatic cavernous hemangioma. Therefore, biopsy of these lesions are commonly required in order to determine the final diagnosis [93,95].

B-mode US and CEUS

The US findings have been assessed in only a small number of reports [10,11,38,95-97]. On B-mode US, HEHE can appear as a single or multiple, diffuse hypoechoic lesion (or hyperechoic in a minority of cases). It may be inhomogeneous with irregular margins, usually located near the liver capsule, which may be distorted and invaginated [11,95]. Therefore, multiple subcapsular hypoechoic FLLs of regular shape should raise the possibility of HEHE. On CEUS, HEHE usually presents with peripheral rim-like hyperenhancement in the arterial phase (which can be absent), and the central areas of the lesion appear hypoenhanced [11,95,97]. In the portal venous and late phases, HEHE presents a rapid washout with hypoenhancement, raising suspicion of a malignant tumor (fig 4). Central unenhanced areas are often observed in the late phases [11]. In some cases, CEUS may reveal more lesions than the unenhanced US [11].

Conclusion

The diagnosis of rare malignant mesenchymal liver lesions of the liver are a challenge owing to the rarity of these lesions. An US examination with, if required, color Doppler sonography (CDS) and CEUS, taking into account the clinical background of the patient, may help to focus the differential diagnoses. In most of these lesions, the enhancement pattern is characterized by the absence of portal venous perfusion, known as the washout phenomenon. This is similar to common malignant liver lesions and thus indicates the need for histological confirmation.

Conflict of interest: none

References

4. Dietrich CF, Nolsøe CP, Barr RG, et al. Guidelines and Good Clinical Practice Recommendations for Contrast-
Enhanced Ultrasound (CEUS) in the Liver-Update 2020


